These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 26242764

  • 1. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
    Abdel-Azim H, Mahadeo KM, Zhao Q, Khazal S, Kohn DB, Crooks GM, Shah AJ, Kapoor N.
    Am J Hematol; 2015 Nov; 90(11):1021-6. PubMed ID: 26242764
    [Abstract] [Full Text] [Related]

  • 2. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B.
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [Abstract] [Full Text] [Related]

  • 3. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ, Armand P, Cutler CS, Ho VT, Glotzbecker B, Nikiforow S, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP.
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [Abstract] [Full Text] [Related]

  • 4. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
    Lee JW, Kang HJ, Kim S, Lee SH, Yu KS, Kim NH, Jang MK, Kim H, Song SH, Park JD, Park KD, Shin HY, Jang IJ, Ahn HS.
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
    [Abstract] [Full Text] [Related]

  • 5. A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor.
    Mahadeo KM, Weinberg KI, Abdel-Azim H, Miklos DB, Killen R, Kohn D, Crooks GM, Shah AJ, Kharbanda S, Agarwal R, Kapoor N.
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):440-4. PubMed ID: 25459642
    [Abstract] [Full Text] [Related]

  • 6. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, Setia R, Katewa S.
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [Abstract] [Full Text] [Related]

  • 7. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
    Kothari A, Ngwube A, Hayashi R, Murray L, Davis J, Haut P, Loechelt BJ, Shenoy S.
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
    [Abstract] [Full Text] [Related]

  • 8. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS, Agarwal R, Weinberg KI, Wagner JE.
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
    [Abstract] [Full Text] [Related]

  • 9. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, Vermont C, Ahmad I, Shaw PJ, Telles da Cunha JM, Schlegel PG, Hough R, Fasth A, Kentouche K, Gruhn B, Fernandes JF, Lachance S, Bredius R, Resnick IB, Belohradsky BH, Gennery A, Fischer A, Gaspar HB, Schanz U, Seger R, Rentsch K, Veys P, Haddad E, Albert MH, Hassan M, Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation.
    Lancet; 2014 Feb 01; 383(9915):436-48. PubMed ID: 24161820
    [Abstract] [Full Text] [Related]

  • 10. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, van de Ven C, Fabricatore S, Wolownik K, Cooney-Qualter E, Baxter-Lowe LA, Luisi P, Militano O, Kletzel M, Cairo MS.
    Biol Blood Marrow Transplant; 2016 Apr 01; 22(4):698-704. PubMed ID: 26785332
    [Abstract] [Full Text] [Related]

  • 11. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
    Aldenhoven M, Jones SA, Bonney D, Borrill RE, Coussons M, Mercer J, Bierings MB, Versluys B, van Hasselt PM, Wijburg FA, van der Ploeg AT, Wynn RF, Boelens JJ.
    Biol Blood Marrow Transplant; 2015 Jun 01; 21(6):1106-9. PubMed ID: 25708213
    [Abstract] [Full Text] [Related]

  • 12. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC.
    Biol Blood Marrow Transplant; 2013 Jul 01; 19(7):1094-101. PubMed ID: 23635453
    [Abstract] [Full Text] [Related]

  • 13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.
    Biol Blood Marrow Transplant; 2013 Jun 01; 19(6):981-7. PubMed ID: 23562738
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
    Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL.
    Biol Blood Marrow Transplant; 2007 Jun 01; 13(6):724-33. PubMed ID: 17531783
    [Abstract] [Full Text] [Related]

  • 15. Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.
    Cuellar-Rodriguez J, Freeman AF, Grossman J, Su H, Parta M, Murdock H, Shah N, Bollard C, Kong HH, Moutsopoulos N, Stone K, Gea-Banacloche J, Holland SM, Hickstein DD.
    Biol Blood Marrow Transplant; 2015 Jun 01; 21(6):1037-45. PubMed ID: 25636378
    [Abstract] [Full Text] [Related]

  • 16. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P, Bhatia M, Garvin JH, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.
    Biol Blood Marrow Transplant; 2012 Feb 01; 18(2):324-9. PubMed ID: 22079471
    [Abstract] [Full Text] [Related]

  • 17. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A, Samuel S, Elad S, Slavin S.
    Biol Blood Marrow Transplant; 2006 Jul 01; 12(7):712-8. PubMed ID: 16785060
    [Abstract] [Full Text] [Related]

  • 18. Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
    Novitzky N, Thomas V, du Toit C.
    Biol Blood Marrow Transplant; 2013 Apr 01; 19(4):584-8. PubMed ID: 23270985
    [Abstract] [Full Text] [Related]

  • 19. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V, Hütker S, Schmid I, Immler S, Feuchtinger T, Albert MH.
    Ann Hematol; 2017 Aug 01; 96(8):1373-1377. PubMed ID: 28573314
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A, Olivé T, Martinez A, Bureo E, Maldonado MS, Diaz de Heredia C, Sastre A, Gonzalez-Vicent M, Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Pediatr Hematol Oncol; 2007 Sep 01; 24(6):393-402. PubMed ID: 17710656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.